ESMO: Incyte's PD-1 treads new ground in anal cancer - Pharmaphorum
Incyte's PD-1 inhibitor Zynyz, after initial FDA rejection for SCAC, shows potential in first-line setting with chemo, improving PFS and OS in POD1UM-303 study. Incyte's CDK2 inhibitor INCB123667 shows promise in ovarian cancer, with plans for phase 3 trials starting in 2025.
Reference News
ESMO: Incyte's PD-1 treads new ground in anal cancer - Pharmaphorum
Incyte's PD-1 inhibitor Zynyz, after initial FDA rejection for SCAC, shows potential in first-line setting with chemo, improving PFS and OS in POD1UM-303 study. Incyte's CDK2 inhibitor INCB123667 shows promise in ovarian cancer, with plans for phase 3 trials starting in 2025.